SOURCE: Seegene


May 30, 2012 07:00 ET

Seegene Develops Industry's First Real-Time "Multiplex Quantification" Molecular Diagnostic Testing Technology

A Game Changing Technology Creates a New Class of Preemptive and Proactive Molecular Tests

GAITHERSBURG, MD and SEOUL, SOUTH KOREA--(Marketwire - May 30, 2012) - Seegene Inc. (KOSDAQ: 096530), a leading developer of multiplex molecular diagnostic technologies and tests, today announced the development of a new molecular technology that for the first time allows high multiplexing and multiple quantification from a single sample in a single tube.

Seegene's real-time multiplex PCR technology allows the simultaneous detection and quantification of up to 20 analytes on an existing 4-channel real-time instrument. This technology can provide life science companies with a competitive edge in a wide range of molecular testing applications and industry sectors. Seegene intends to make the technology broadly available to the life science market on a co-development or out-license basis.

"This represents a new class of molecular diagnostics (MoDx) technology that for the first time delivers highly multiplexed quantitative tests that can be run on potentially any real-time instrument. Using this new technology as their core MoDx technology, a wide variety of life science firms can develop comprehensive multiplexed diagnostic tests that can both detect and quantify all possible analytes in a single tube," said Dr. Jong-Yoon Chun, founder, CTO and CEO of Seegene.

"By enabling the quantification of multiple targets, the technology opens vast new and previously unimagined possibilities for new molecular tests. Opening this technology to a wide spectrum of companies operating in diverse markets is a game changer in molecular testing, and will promote a paradigm shift to well-conceived, intuitive tests that can be utilized in a preemptive or proactive manner," added Dr. Chun.

Seegene will introduce the first assay based on the technology at the 2012 AACC Annual Meeting (July 15-19, Los Angeles): A highly multiplexed assay that will detect, differentiate and quantitate 19 high risk and 9 low risk Human Papilloma Virus genotypes.

About Seegene
Seegene is the world's leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene's core enabling technologies -- ACP™, DPO™, READ, and TOCE™ -- are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene's products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene's mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.

For more information please visit or call +301-762-9066.

Contact Information

  • Contacts:
    David L. Dolinger, Ph.D.
    Seegene Inc.
    Email Contact
    Constantine Theodoropulos
    Boston Communications
    Email Contact